Abstract: Fertility preservation is feasible in the majority of men. Herein, we review the reproductive toxicities of commonly encountered clinical threats to male fertility, including cancer, radiotherapy, chemotherapy, surgery, and nonmalignant diseases treated with immunosuppression. Other scenarios, in which fertility preservation may be considered, such as Klinefelter syndrome, acute testicular injury, and sudden unexpected death, are also discussed. We provide an algorithmic approach to fertility preservation in men, and review strategies for sperm acquisition in cases of ejaculatory dysfunction and azoospermia. Lastly, emerging options for fertility preservation in prepubertal boys are discussed.
Introduction
The decision to acquire and store sperm for future reproduction in men facing a threat to their fertility is complex. The most compelling benefit of cryopreservation is preservation of the potential for biological paternity in patients at risk for future azoospermia. A less commonly considered benefit is maintenance of the opportunity for assisted reproduction with intrauterine insemination (IUI), rather than in vitro fertilization (IVF), by storage of normozoospermic semen samples in patients at risk for oligozoospermia. A third benefit of fertility preservation in men is amelioration of anxiety about future infertility. Approximately one-third of young men with cancer experience significant distress concerning their fertility 1 and two-thirds of cancer patients who cryopreserve sperm feel significantly encouraged by having done so. 2 These benefits must be weighed against the medical and financial costs of male gamete acquisition and cryopreservation. In most men sufficient sperm can be acquired by collection of ejaculated semen, which is associated with minimal medical or financial cost. In men who cannot ejaculate or who are azoospermic, more invasive procedures such as electroejaculation and surgical testicular sperm extraction (TESE) are required. These procedures have potential associated www.clinicalobgyn.com | 815 medical morbidity, may be ineffective, and may be financially expensive. In this article, we review the commonly encountered clinical threats to male fertility and the techniques used for the acquisition and storage of human sperm in men interested in fertility preservation.
Clinical Threats to Male Fertility

CANCER
Cancer is the most commonly encountered clinical threat to male fertility. Approximately 766,000 American men were diagnosed with cancer in 2009, including 65,000 men of prime reproductive age . 3 Recent advances in the detection and treatment of many cancers have resulted in improved survival rates, allowing patients and their physicians to extend their focus toward optimization of quality of life after cancer treatment. Cancer patients are at significant risk for infertility due to their underlying disease and the reproductive toxicity of antineoplastic therapy. For most men the diagnosis of malignancy does not significantly alter their desire to have children. Three-quarters of childless young adults facing a new diagnosis and 25% of men who already have children consider preservation of the capacity for biological paternity to be a critical quality of life issue. 4 However, only 47% of American oncologists routinely refer cancer patients of childbearing age to a reproductive specialist. 5 Due to the imminent threat to male fertility posed by cancer and its treatment, discussion of fertility preservation with men facing a new diagnosis of malignancy is of paramount importance. This is reflected in statements from both the American Society of Clinical Oncology (ASCO) and the American Society of Reproductive Medicine (ASRM). 6, 7 ASCO recommends that ''oncologists discuss at the earliest opportunity the possibility of infertility as a risk of cancer treatment,'' and that patients interested in fertility preservation should be referred to a fertility specialist as early as possible. The ASCO panel furthermore emphasized that, aside from hereditary genetic syndromes, there is no evidence that a history of cancer, cancer therapy, or fertility interventions increase the risk of cancer or congenital malformations in offspring. Guidelines from the ASRM similarly emphasize that, ''physicians should inform cancer patients about options for fertility preservation and future reproduction prior to treatment.'' The ASRM panel furthermore stated that concerns regarding the welfare of potential future offspring, such as concerns about posthumous parenting, should not impede discussions with cancer patients about options for fertility preservation. Cancer itself may disrupt fertility even before the initiation of antineoplastic treatment, though data are conflicting about the impact of cancer on pretreatment semen analysis parameters. Most studies have demonstrated a significant effect but some have not; moreover some studies suggest that the type of malignancy matters, whereas other studies have failed to do so. In the most contemporary American series to address this issue, Williams retrospectively reviewed semen analyses from 409 men who had successfully banked spermatozoa at their institution before initiation of potentially gonadotoxic antineoplastic therapy. Williams found that men with most types of cancer had pretreatment semen parameters in the National Cooperative Reproductive Medicine Network (NCRMN) fertile range (16 from B) for concentration (mean 47 million sperm per mL) and in the intermediate range for motility (16 from B) (mean motility score 50%). However, men with testicular cancer had significantly reduced sperm concentrations (mean 33 million sperm per mL, NCRMN intermediate range) compared with men with other malignancies. Moreover, 45% of men with testicular cancer had sperm concentrations in the NCRMN subfertile range ( <13.5 million per mL), versus 16% of men with other malignancies and 10% of normal men without cancer who underwent vasectomy. In contrast to the Williams study, other studies have found that patients with Hodgkin lymphoma, nonHodgkin lymphoma, and leukemia have lower sperm concentrations than healthy, age-matched semen donors. 10 In the current era of intracystoplasmic sperm injection (ICSI), achievement of pregnancy is feasible with very few spermatozoa. Even men who are rendered severely oligozoospermic by their malignancy remain suitable candidates for pretreatment cryopreservation of sperm. In men with azoospermia, however, cryopreservation of ejaculated sperm is not possible by definition. Pretreatment azoospermia is a generally underappreciated phenomenon because most studies of semen parameters in cancer patients have excluded azoospermic men. 9, 10 The limited data suggest that azoospermia affects 10% to 12% of men of reproductive age with cancer and is much more common than in the general population. Rates of pretreatment azoospermia vary by the underlying malignancy, with high rates observed in men with testicular cancer (10%-15%) and hematological malignancies (9%-13%), and lower rates in other malignancies.
11,12
RADIATION THERAPY
Radiation therapy (RT) is used for a wide variety of cancer types in men, including hematologic malignancies, and carcinomas of the testis, penis, prostate, bladder, and rectum. The testes exhibit significant, dose-dependent radiosensitivity and even very low-dose exposure carries a significant risk. Changes in number and shape of spermatogonia have been histologically demonstrated with doses as low as 0.1 Gy. Significant spermatocyte damage, and an associated sharp decrease in spermatid count, occurs with exposure to 2 to 3 Gy of RT. Exposure to greater than 4 Gy of RT leads to significantly fewer or absent sperm. The effects may be transient or irreversible. Changes in ejaculated semen analyses mirror these histological findings and first manifest approximately 70 days after RT (a timeline consistent with the life span of sperm that developed before radiation exposure). Oligozoospermia is typically seen with RT doses below 0.8 Gy, transient azoospermia results from 0.8 to 2 Gy, and irreversible azoospermia is a significant risk with doses greater than 2 Gy. 8 Testicular exposure to radiation during treatment for common malignancies in men of reproductive age is often significant, despite the use of gonadal shielding. The most common indications for RT in this population are for the treatment of retroperitoneal lymphatic metastases of testicular seminoma, for the treatment of Hodgkin and non-Hodgkin lymphoma, and during total body irradiation before bone marrow or stem cell transplantation for the treatment of advanced hematologic malignancy. Less commonly, men of reproductive age with rectal or prostate carcinoma treated with pelvic RT are exposed to inadvertent testicular irradiation that may be gonadotoxic. In other cases, purposeful testicular RT is delivered for primary testicular processes such as intratubular germ cell neoplasia. Typical testicular RT exposure in these conditions and the anticipated impact on fertility are summarized in Table 1 .
CHEMOTHERAPY
Chemotherapeutic agents impart a wide range of dose-dependent effects on sperm production. Various agents, however, can be broadly assigned to risk categories relative to impaired spermatogenesis Fertility Preservation in Men 817 (Table 2 ). Alkylating agents are highly toxic and comprise the highest risk group. These agents cause cellular death by impairing DNA synthesis and RNA transcription. The developing germinal epithelium is subject to mutations when exposed to alkylating agents and severe oligozoospermia or azoospermia are the typical results. Platinum analogs cause DNA cross-link formation and may be equally destructive to spermatogenesis, though 80% of men treated with platinum-based chemotherapy recover spermatogenesis within 5 years of stopping treatment. Vinca alkaloids, such as vincristine and vinblatine, act by inhibiting formation of microtubules and thereby disrupting mitosis. These drugs are often given concomitantly with high-risk agents and, in the multidrug setting, are associated with significant insult to spermatogenesis. When they are not given in combination with alkylating agents or platinum analogs, however, the vinca alkaloids cause only a temporary reduction in sperm concentration. Antimetabolites exert antineoplastic effects by interfering with DNA synthesis and transcription. In conventional doses they cause temporary reductions in sperm concentration, but recovery of normal spermatogenesis is the norm. Newer agents, such as monoclonal antibodies, tyrosine kinase inhibitors, and taxanes have an unknown effect on spermatogenesis.
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SURGERY
Pelvic surgery for benign or malignant disease may be detrimental to male fertility. It is imperative that surgeons discuss the reproductive implications of surgery with their patients. Men with testicular cancer who undergo retroperitoneal lymphadenectomy (RPLND) are at risk of disruption of the autonomic, sympathetic inputs critical for ejaculation. Though modern nerve sparing techniques have limited the risk substantially, these patients remain at significant risk of postoperative anejaculation or retrograde ejaculation (RE). The autonomic nerves of the pelvis responsible for erection are at risk during extirpative pelvic surgery, such as radical prostatectomy, proctectomy, or cystoprostatectomy. These patients must be counseled about the significant risk of postoperative erectile dysfunction, which threatens their future potential to achieve pregnancy. Furthermore, radical pelvic surgery for the treatment of prostate or bladder cancer includes purposeful and permanent disruption of the male genital ductal system, after which reproduction is only possible with assisted technology.
NONMALIGNANT DISEASES TREATED WITH IMMUNOSUPPRESSION
Immunosuppressive therapies are cytotoxic and may damage the testicular germinal epithelium. These agents are used in the treatment of a wide variety of disorders including inflammatory bowel disease and the rheumatoid diseases, and are commonly used to prevent rejection in solid organ or hematopoietic transplant recipients. Data are relatively scarce regarding the effects of these disease processes and drugs on male fertility. One study of semen parameters in 23 patients with various nonmalignant systemic diseases demonstrated that these patients have poorer semen analysis parameters than healthy sperm donors, but their values were still within the World Health Organization normal ranges and more than adequate for cryopreservation. 13 The authors recommended that sperm banking be offered to all patients with nonmalignant systemic diseases before the initiation of cytotoxic therapy. IBD can threaten male reproductive capacity in several ways. Sulfasalazine and other 5-aminosalicylic acid have been linked to oligozoospermia, which is usually reversible with the cessation of therapy. Though controversial, there is some 
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evidence that methotrexate disturbs spermatogenesis and that infliximab impairs sperm motility. Surgical treatments such as proctocolectomy with ileal J-pouch and anal anastomosis may disrupt the autonomic nerves of the pelvis and cause erectile or ejaculatory dysfunction, which occurs in 4% to 25% of cases. The reproductive sequelae of rheumatoid diseases, solid organ transplantation, and other autoimmune disorders in men have not been well characterized. For these patients, decisions about pretreatment acquisition and storage of sperm should be made based on the gonadotoxicity of the anticipated treatment. The effects of some commonly used immunomodulatory drugs on male fertility are summarized in Table 3 . 13 KLINEFELTER SYNDROME
Klinefelter syndrome (KS) is the most common sex chromosome abnormality in humans and affects 1/600 newborn males. It is a profoundly underdiagnosed condition. Epidemiological studies suggest that only a quarter of adult males with KS are ever diagnosed, and diagnosis is only rarely made before onset of puberty. 14 Infertility in KS is the result of germ cell degeneration that begins in utero, progresses slowly during infancy and early childhood, and accelerates during puberty and adolescence. Eventually hyalinization of seminiferous tubules, interstitial fibrosis, and complete loss of germ cells occurs. This results in the small, firm testicles that characterize KS and azoospermia in greater than 90% of cases. Due to the predictable progressive decline in spermatogenic function seen in KS, fertility preservation strategies should ideally be employed as soon as possible in affected patients. 15 We advocate that cryopreservation of sperm be considered in the adolescent period via ejaculation or microdissection-TESE, although this approach is investigational and should be restricted to tertiary centers. Sperm retrieval rates may be as high as 66% in KS 16 and, to date, the follow-up of boys born via assisted reproduction techniques to men with KS has not shown any increased risk of congenital anomalies or KS. 15 
DEATH
Sudden unexpected death may prompt requests from the decedent's spouse or family for retrieval of sperm to be used for future reproduction. Sperm maintain nearly normal motility for the first 3 hours postmortem and are retrievable in nearly 100% of cases attempted within 24 hours of death. Successful postmortem sperm retrieval (PMSR) has been reported up to 36 hours after death, though the likelihood of success is lower once 24 hours have transpired. 17 Several methods of PMSR have been reported, including epididymal harvest, irrigation or aspiration of the vas deferens, electroejaculation, and TESE.
Reproductive physicians should be familiar with the complex ethical and legal issues surrounding PMSR. In 1995, we convened a panel of experts at our institution and established guidelines to facilitate decision-making in this challenging clinical scenario. Only men undergoing fertility treatment, actively attempting conception, or who had specifically expressed their plans to attempt conception 
OCCUPATIONAL RISK OF MORTALITY
Prophylactic cryopreservation of sperm may be considered in men with occupations that place them at high risk for mortality, such as men serving active duty in the military. In these scenarios patients should be counseled about posthumous parenting before sperm acquisition.
Acquisition and Cryopreservation of Sperm
Sperm for fertility preservation may be acquired in a variety of ways. In most patients collection of ejaculated semen provides more than enough sperm for cryopreservation and subsequent reproduction.
However, in patients with ejaculatory dysfunction or azoospermia, acquisition of sperm for cryostorage is more difficult and requires additional intervention. Our suggested approach for acquisition of sperm for fertility preservation is presented in Figure 1 .
COLLECTION AND STORAGE OF EJACULATED SPERM
In the majority of men, sperm for fertility preservation may be acquired by collection of ejaculated semen after self-stimulation. The semen collection environment should be optimized by eliminating time constraints for sample production and by provision of appropriate stimulating materials. For adolescents, parents should be encouraged not to attend the appointment for sample collection. Historical, minimally acceptable parameters for cryopreservation of ejaculated semen are less relevant since the advent of ICSI, and poor semen parameters have not been shown to affect fertilization and pregnancy rates after cryopreservation. 19 Therefore, all collected samples containing viable sperm should be cyropreserved. 20 Analysis of the liquefied semen sample at 371C should be performed to establish sperm concentration, motility, and morphology before cryopreservation. After liquefaction and analysis, sterile samples with normal sperm concentration are gently mixed with an equal volume of a cryoprotective medium to protect against damage incurred during freezing from formation of intracellular and extracellular ice crystals. Sufficient specimen should be collected and processed to allow for 10 inseminations if possible. Depending upon the volume and concentration of ejaculated semen provided, several samples may be required. Semen diluted with cryoprotectant is carefully aliquoted into 300 mL straws under sterile conditions. Most centers use stepwise freezing and automated, programmable freezers with cooling rates of 8 to 211C per minute until
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www.clinicalobgyn.com -1961C is reached, after which the cryopreserved samples are stored in liquid nitrogen. Patients typically enter into an agreement with the storage facility that is renewed on an annual basis. Storage fees range from $50 to several hundred dollars annually. 20 Modifications to the processing and freezing protocols are indicated in cases when analysis of the ejaculated sample reveals oligozoospermia or significant deficits in sperm morphology or motility. Before addition of cryoprotectant, sperm with the best features may be isolated with selection procedures such as swim-up tests and centrifugation on a density gradient. Sperm concentration is then artificially augmented by centrifugation and resuspension of the isolated sperm pellet in appropriate medium. Specialized cryoprotectants containing human albumin are typically added to the optimized semen samples, after which freezing is carried out according to standard protocol. Similar optimization procedures are used for cryopreservation of surgically retrieved epididymal or testicular sperm. 20 In men with cancer or benign diseases requiring cytotoxic therapy, cryopreservation should be performed before the initiation of treatment. Most chemotherapeutic regimens have been demonstrated to induce potentially transmissible aneuploidies, structural chromosomal abnormalities, and genetic prelesions in male germ cells of men during and immediately after chemotherapy. Postmeiotic spermatids lack DNA repair mechanisms and are the most susceptible. Effects are most pronounced in the first several weeks of treatment, at which point sperm concentration and motility are often unaffected. Although observational studies in humans have not demonstrated an increased risk of congenital or genetic anomalies in offspring of men who have received chemotherapy, the data are methodologically limited and studies in rodents have consistently demonstrated adverse reproductive outcomes. Cryopreservation (or attempted reproduction) should therefore not be performed until a minimum of 3 months after cessation of chemotherapy. Most physicians advocate a waiting period of at least 1 year. 
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COLLECTION OF SPERM FROM PATIENTS WITH EJACULATORY DYSFUNCTION
Some candidates for fertility preservation are unable to ejaculate for social, religious, or medical reasons. These individuals include peri-pubertal adolescents unfamiliar with masturbation, patients whose religion strictly disallows masturbation, patients with psychogenic anejaculation, and patients with organic ejaculatory dysfunction. The latter group includes patients with spinal cord (SC) lesions and patients who previously underwent RPLND for testicular cancer. Ejaculatory dysfunction may be due to either RE or anejaculation.
In patients able to achieve orgasm without antegrade ejaculation, the presumed diagnosis is RE. The goal of treatment of patients with RE is induction of antegrade ejaculation with sympathomimetic drugs initiated the night before and the morning of sperm harvest. Ephedrine sulfate (25 mg PO BID), imipramine hydrochloride (50 mg PO QD and titrate to 50 mg PO TID), midodin hydrochloride (7.5 mg orally, to a maximum of 20 mg), or pseudoephedrine hydrochloride (90 mg PO QID) have been used successfully in the treatment of RE. If attempts at pharmacologic restoration of antegrade ejaculation are unsuccessful, then sperm may be harvested from the postejaculate urine. Alkalinization of urine with 5 to 10 mL of poly-citra is used with each dose of sympathomimetics. 22 For anorgasmic or anejaculatory patients options for sperm acquisition include penile vibratory stimulation (PVS), electroejaculation (EEJ), and surgical sperm retrieval. PVS is an effective harvesting technique for appropriately selected patients. A commercially available stimulator is applied to the frenular surface of the penis and ejaculation is induced. The procedure may be performed by the physician in his office, or by the patient at home. PVS is mediated by a reflex arc in which afferent input from the penis travels via the dorsal penile and pudendal nerves to the S2-S4 region of the SC. Spinal interneurons relay the input to efferent sympathetic nerves that exit the SC at T10-L2 and synapse within the paraspinal sympathetic chains in the retroperitoneum. Postganglionic sympathetic fibers then travel to the hypogastric plexus and ultimately through the pelvis as the hypogastric nerves to innervate the prostate, seminal vesicles, bladder neck, and vasa deferentia. The reflex arc is subject to inhibitory cortical control. Therefore, PVS is best suited for patients in whom the reflex arc is intact and in whom cortical inhibition is disrupted, such as patients with SC injury above T10. 22 EEJ directly stimulates the ejaculatory apparatus, does not require intact innervation, and is effective for anejaculation of any etiology. Despite its near-universal effectiveness, EEJ is exceedingly painful and requires general anesthesia for men who are sensate below the waist. In patients with absent sensation below the waist, EEJ is cost-effective and should be considered when PVS fails. A rectal probe is inserted completely into the rectum with the electrodes oriented anteriorly and electrostimulation is delivered directly to the prostate and seminal vesicles. Stimulation is carried out with a standard electrical stimulation system starting at maximum energy of 5 volts. The voltage maximum is increased in a step-wise manner up to 30 volts. Typically, penile tumescence is noted first, followed by seminal emission which may be either pulsatile or occur as a slow drip. Electrostimulation is stopped when seminal emission ceases, rectal temperature of 381C is observed, or a maximum of 30 volts is attained. Anoscopy is performed to confirm that there is no rectal mucosal injury. Urethral catheterization is carried out for collection of any sperm that traveled retrograde into the bladder. Sperm
Fertility Preservation in Men 823
acquired with EEJ may be used for IUI or IVF/ICSI, depending upon the parameters of collected semen.
22
Sperm may also be acquired in anejaculatory patients by standard techniques for surgical sperm retrieval including microsurgical epididymal sperm aspiration (MESA) and microsurgical or nonmicrosurgical TESE. Surgically acquired sperm are generally not used for IUI, and so this approach commits patients to IVF if they decide to reproduce with their stored sperm.
COLLECTION OF SPERM IN AZOOSPERMIC PATIENTS
Acquisition of sperm for fertility preservation in azoospermic patients requires direct retrieval of sperm from the epididymis or testis. Retrieval may be performed percutaneously or surgically, with or without the use of the operating microscope. The choice of retrieval technique depends upon the nature of the azoospermia (obstructive versus nonobstructive), the reproductive desires of the patient, and the experience of the reproductive surgeon. Options include percutaneous epididymal sperm aspiration (PESA), MESA, percutaneous TESE using either testicular fine needle aspiration (TFNA) or percutaneous biopsy, and microsurgical and nonmicrosurgical TESE.
Patients with normal size testicles, normal hormone profiles, and suggestive findings on history or physical examination such as prior inguinal surgery or nonpalpable vasa deferentia are likely to have obstructive azoospermia. In chronic obstruction of the male genital ductal system, the distal epididymis becomes laden with macrophages and degenerating sperm but motile sperm accumulate in the proximal epididymis, where concentrations of motile sperm up to 1 million per microliter may be found and aspirated. Patients with obstructive azoospermia are candidates for PESA, TFNA, percutaneous biopsy, and MESA.
TFNA is the least involved of these procedures to perform, but yields the lowest number of sperm. 23 After the induction of local anesthesia to the scrotal skin as well as a spermatic cord block, the testis is stabilized between the surgeon's thumb and forefinger and a needle is inserted along the long axis of the testis. The needle is withdrawn slightly and redirected to disrupt the testicular architecture. The procedure is repeated until adequate testicular material has been aspirated. Percutaneous biopsy involves the use of a 15-gauge biopsy gun with a short excursion which is used to retrieve testicular tissue. Anesthesia is achieved with a spermatic cord block as well as topical application of local anesthetic. Multiple biopsies can be obtained through a single entry site and this procedure provides higher sperm yield than needle aspiration. PESA can also be performed under local anesthesia with low cost and without microsurgical skills. In this procedure, a 21-gauge butterfly needle is attached to a 20 mL syringe and is inserted into the caput epididymis and then slowly withdrawn until fluid can be seen in the tubing. The tubing is then clamped and the fluid flushed out with medium.
MESA is the preferred technique for sperm retrieval in men with obstructive azoospermia because of its ability to retrieve greater numbers of sperm, the direct visualization of the epididymal puncture, and the minimal contamination of the sample with blood. MESA is performed as an open operation under an operating microscope. Individual tubules of the epididymis are isolated and micropuncture aspiration is performed. Initial aspiration is performed starting halfway up the obstructed reproductive segment, and subsequent punctures are carried out proximally. MESA typically results in sperm retrieval of more than 100 Â 10 6 sperm with adequate motility for effective cryopreservation of multiple samples. 24 
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For men with nonobstructive azoospermia who wish to preserve their fertility, TESE is required. TFNA and percutaneous biopsy are less effective than open surgical sperm retrieval and are not recommended. 25 Open testicular biopsies, either single or multiple, have been performed in a number of different ways for TESE. We advocate performance of TESE with the aid of an operating microscope (Fig. 2) . This approach results in a higher number of sperm harvested, an increased chance of retrieving sperm, and decreased removal of testicular tissue compared with conventional TESE. 25 Data on use of TESE for fertility preservation are scarce and consist of case reports and small case series. In most men who attempt sperm cryopreservation but are found to be azoospermic, attempts at fertility preservation are aborted. Future biological paternity is only possible in such cases if sufficient spermatogenic capacity survives the gonadotoxic insult and allows for subsequent assisted or unassisted reproduction. Although this will often be the case, such as is typical in men with successfully eradicated germ cell tumors, some azoospermic patients in whom sperm may have initially been retrievable will inevitably be rendered permanently sterile by the disease or treatment that threatened their fertility. Therefore, TESE should be strongly considered in azoospermic patients facing a significant clinical threat to their fertility. In the largest relevant published series, Schrader et al 26 reported successful retrieval of sperm in 6/14 men with testicular cancer and 8/17 patients with lymphoma, thereby demonstrating the feasibility and efficacy of this approach. In patients with testicular cancer, retrieval may safely be performed ex vivo at the time of radical orchiectomy upon the tumor-containing testis. 
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The Future: Fertility
Preservation in Prepubertal Boys
As a result of improvements in cancer treatment, more than 75% of children and adolescents diagnosed with cancer have long-term survival. In boys who have reached puberty, methods for preserving fertility are identical to those employed in adults. Anejaculation is common in this clinical scenario and best managed with surgical sperm retrieval. Preserving fertility in prepubertal boys facing chemotherapy treatment presents a much greater challenge and no effective treatment currently exists, although several potential future strategies are recognized. All of these approaches involve acquisition and preservation of immature male gametes in the hope that future technology will enable reproduction. Three general strategies have been employed: autotransplantation of purified germ cell suspensions (germ cell transplantation), autotransplantation of testicular parenchyma, and in vitro maturation of immature germ cells for ICSI. 27 Germ cell transplantation was first successfully performed in rodent models and subsequently the feasibility of transplanting germ cell suspensions into nonhuman primates was demonstrated. This suggests the possibility of retrieving germ cells from a patient before sterilizing treatment, cryopreserving them, and ultimately using them for autologous transplantation after the patient has recovered. Testicular tissue grafting is another feasible approach and involves autotransplantation or xenografting of nonmanipulated testicular tissue. This approach preserves the microenvironment of spermatogonial stem cells, but risks reintroduction of occult malignant cells if used for autotransplantation. It has not yet been successfully applied in humans. Nonetheless xenografting of immature testicular tissue into immunodeficient mice yielding complete spermatogenesis within the graft has been described in several nonprimate mammals, suggesting the possibility of sperm retrieval from the graft to be used with ICSI. Finally, recent progress in the development of cell-culture systems for spermatogonia suggests that in vitro spermatogenesis from cryopreserved immature germ cells may be possible in the foreseeable future. 27 Although cryopreservation of immature testicular germ cells or testicular parenchyma remains experimental and is not standard clinical practice, we advocate discussion of cryopreservation with prepubertal boys and their parents.
Conclusions
Sperm acquisition and cryopreservation are feasible in the majority of men with medical conditions that impact fertility. These modalities are underused in clinical practice. Among the obstacles is a relative lack of physician awareness and referral to reproductive specialists. There are multiple procedures available for sperm retrieval that can be tailored to individual patient conditions. Ongoing research is directed at the goal of preserving fertility potential in prepubertal boys.
